Cytek Biosciences (CTKB) Payables (2020 - 2026)

Cytek Biosciences has reported Payables for 7 years, with the latest figure at $6.7 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 7.91% year-over-year to $6.7 million; the trailing twelve-month figure through Mar 2026 stood at $6.7 million (up 7.91% YoY), and the FY2025 full-year result was $6.4 million, up 15.93% from the prior year.
• Payables for Q1 2026 stood at $6.7 million, up from $6.4 million in the prior quarter.
• The five-year high for Payables was $7.6 million in Q3 2025, with the low at $3.0 million in Q4 2023.
• Historically, Payables has averaged $5.4 million across 5 years, with a median of $5.5 million in 2024.
• Annual changes were most pronounced in 2023 — Payables tumbled 54.33% — and 2025, when it soared 114.76%.
• Cytek Biosciences' Payables stood at $4.8 million in 2022, then tumbled by 36.9% to $3.0 million in 2023, then surged by 82.35% to $5.5 million in 2024, then grew by 15.93% to $6.4 million in 2025, then climbed by 5.16% to $6.7 million in 2026.
• The last three Payables figures came in at $6.7 million (Q1 2026), $6.4 million (Q4 2025), and $7.6 million (Q3 2025), per Business Quant data.